Aclaris Therapeutics enters separation agreement with retiring executive Frank Ruffo

Aclaris Therapeutics, Inc.

Frank Ruffo's retirement separation agreement approved; includes consulting deal through March 2, 2023 for $25,000.
Ruffo will continue vesting of outstanding options and RSUs during the consulting period.
Exercise period for vested options extended to December 31, 2023.
Ruffo retains eligibility for 2022 annual bonus and accrued pay/vacation.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Frank Ruffo

Other Named Officer

ACRS · Aclaris Therapeutics, Inc.

Filed: December 13, 2022, 6:59 PM ET

In connection with Mr. Ruffo’s previously announced retirement, on December 9, 2022, Aclaris Therapeutics, Inc. (the “ Company ”) and Mr. Ruffo entered into a Separation Agreement and General Release

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.85

Frank Ruffo retired as other_named_officer at Aclaris Therapeutics, Inc..

Action: retired

Exact text from the filing

In connection with Mr. Ruffo’s previously announced retirement, on December 9, 2022, Aclaris Therapeutics, Inc. (the “ Company ”) and Mr. Ruffo entered into a Separation Agreement and General Release

View on SEC.gov

Aclaris Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-126640

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.